Middelweerstandige_tuberkulose%D9%85%D9%82%D8%A7%D9%88%D9%85%D8%A9_%D8%A7%D9%84%D8%A3%D8%AF%D9%88%D9%8A%D8%A9_%D8%A7%D9%84%D9%85%D8%B6%D8%A7%D8%AF%D8%A9_%D9%84%D9%84%D8%B3%D9%84Multi-drug-resistant_tuberculosis%D7%A9%D7%97%D7%A4%D7%AA_%D7%A2%D7%9E%D7%99%D7%93%D7%94%E5%A4%9A%E5%89%A4%E8%80%90%E6%80%A7%E8%82%BA%E7%B5%90%E6%A0%B8%EB%8B%A4%EC%A0%9C%EB%82%B4%EC%84%B1_%EA%B2%B0%ED%95%B5Tuberculose_multirresistenteMultiresistent_tuberkulos%C3%87ok_ilaca_diren%C3%A7li_t%C3%BCberk%C3%BClozQ866602
about
P2175
Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosisNegligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosyCarbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic ReviewDrug-resistant TB: deadly, costly and in need of a vaccineManagement of multidrug-resistant TB: novel treatments and their expansion to low resource settingsThe Prevalence of Drug-Resistant Tuberculosis in Mainland China: An Updated Systematic Review and Meta-AnalysisEmerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Psycho-Socio-Economic Issues Challenging Multidrug Resistant Tuberculosis Patients: A Systematic ReviewT-Cell Therapy: Options for Infectious DiseasesTuberculosis: From an incurable scourge to a curable disease - journey over a millenniumTreatment outcomes from community-based drug resistant tuberculosis treatment programs: a systematic review and meta-analysisA Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-AnalysisAssociation between Directly Observed Therapy and Treatment Outcomes in Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-AnalysisEvolution of drug resistance in tuberculosis: recent progress and implications for diagnosis and therapyNew vision for Revised National Tuberculosis Control Programme (RNTCP): Universal access - "reaching the un-reached"What can we offer to 3 million MDRTB household contacts in 2016?Recent developments in the diagnosis and management of tuberculosis.Multidrug-resistant tuberculosis (MDR-TB) disease burden in China: a systematic review and spatio-temporal analysisIs there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis?Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic reviewTreatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysisUse of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic reviewRisk factors for tuberculosis in foreign-born people (FBP) in Italy: a systematic review and meta-analysisAssociation between HIV/AIDS and multi-drug resistance tuberculosis: a systematic review and meta-analysisGlobal financing and long-term technical assistance for multidrug-resistant tuberculosis: scaling up access to treatmentGenetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic reviewProgrammatic Management of Drug-Resistant Tuberculosis: An Updated Research AgendaCombined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.Is DOTS-plus a feasible and cost-effective strategy?Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis.Peripheral neuropathy in a diabetic child treated with linezolid for multidrug-resistant tuberculosis: a case report and review of the literatureA systematic review of reported cost for smear and culture tests during multidrug-resistant tuberculosis treatment.Rapid diagnostics of tuberculosis and drug resistance in the industrialized world: clinical and public health benefits and barriers to implementationProfile of delamanid for the treatment of multidrug-resistant tuberculosisVariation and risk factors of drug resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis.Prevalence of inappropriate tuberculosis treatment regimens: a systematic reviewMultidrug resistance after inappropriate tuberculosis treatment: a meta-analysisCosts to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.The effect of surgery on the outcome of treatment for multidrug-resistant tuberculosis: a systematic review and meta-analysis
P921
Q26740240-D7AF0F62-C8FC-49F8-8886-7E08FA0C3786Q26746099-8E298824-EA9C-47CC-B4F1-04A096BC433DQ26748597-21D16B51-8F32-4909-97CE-5B30F685B522Q26764847-FFDD13C5-5939-4F79-A483-3E075A28CA46Q26765385-163A4E3E-44B9-41D2-8777-15A3FC5D9375Q26765394-78B71BFD-7C23-4D42-9185-8D70A28BDF68Q26767328-03A2E356-9384-4916-956C-6C6D324C2A2EQ26771997-AA70040F-6369-4473-BFBD-0E2D79515670Q26774846-D8BBE470-A7B4-4989-844F-7265C5F80AE7Q26786661-CC7A95A6-7641-443A-9335-0F505E28633EQ26865560-A94C1D87-578B-437E-A044-09408D515518Q26999537-4CA2BEC5-DA20-4E59-A156-FBD556D70991Q27011264-A0482FFD-0B93-4D5A-9629-D789A049AD87Q27013703-52CCB768-3D75-45A9-9F72-8E03B1DAD76DQ27016579-9FDB6141-F545-4195-BFFA-54C8D91A6EF0Q27024259-E859773D-4561-47F4-93A7-BF0E1CD2F4E0Q28066845-26FFA9DF-DA4B-45F0-82D2-D99F60348D85Q28077124-889A2675-3E41-4B2F-B6C4-B438305A86ACQ28365342-8101A738-1A67-44B2-9E3F-CE4A53B5D3CDQ28393235-3536FF5A-36EA-4782-BCD7-A3581906CA25Q28475509-F8C79845-A94C-4DC0-9092-BE466D65C5CFQ28476110-AA52ADD8-090A-4DA0-A4F2-C8E0ECA542DBQ28484857-5A38D1BD-122F-4594-9D4E-55DAF95444C0Q28537863-5502A6F2-FB38-4B7D-93B6-5F1C21EA78B5Q28538427-57A312D5-D3C1-4972-859D-04AFC48A7971Q28543392-4BDF1ADA-DBF0-4BB0-BE98-53494A74C4B6Q28544877-9437B47C-938D-4435-92CD-2CF87D7780FFQ28552438-2996E958-D834-4181-A31D-4F743669A045Q30236048-444E2A1C-5B92-42E0-8A44-9BEE20C2A7C0Q33257254-D6CA22C0-FC20-417C-8702-70E0C9F59FD0Q33449024-D4FF5FA8-B3DD-43DA-85DA-E0FEFBA457C9Q33791908-D3609E2C-7700-4825-9D6D-42DBA37CA15AQ34606498-C4894F86-2B05-4D17-98C3-7EB0B2C6F16BQ34976354-5493D296-6DB1-4923-A2FD-6CC10C477DD4Q35057495-36C512F6-31A3-4B5E-9D4D-F692A769F087Q35546001-0EB3295A-9F70-4AE8-A9EC-4CDD1CC27E5CQ35929837-3C54B095-5794-4B80-87E9-A575A65B1615Q36001543-30B08973-37B3-4F98-84B9-DECBF7EE1A57Q36024119-BD436321-7843-4B56-89A6-96153553D636Q36047674-8C1DBCD8-E803-4BA0-8208-9D9FDA1DE4EE
P921
description
Krankheit
@de
malattia
@it
tuberculose resistente a isoni ...... a no tratamento da tuberculose
@pt
tuberculosis that is resistant ...... erful first-line anti-TB drugs
@en
name
Middelweerstandige tuberkulose
@af
multidrug-resistant tuberculosis
@en
multiresistent tuberkulos
@sv
tuberculose multirresistente
@pt
tuberculose pharmaco-résistante
@fr
tuberculosis fármaco-resistente
@es
tuberkulozo rezistema kontraŭ pluraj medikamentoj
@eo
Çok ilaca dirençli tüberküloz
@tr
שחפת עמידה
@he
مقاومة الأدوية المضادة للسل
@ar
type
label
Middelweerstandige tuberkulose
@af
multidrug-resistant tuberculosis
@en
multiresistent tuberkulos
@sv
tuberculose multirresistente
@pt
tuberculose pharmaco-résistante
@fr
tuberculosis fármaco-resistente
@es
tuberkulozo rezistema kontraŭ pluraj medikamentoj
@eo
Çok ilaca dirençli tüberküloz
@tr
שחפת עמידה
@he
مقاومة الأدوية المضادة للسل
@ar
altLabel
MDR TB
@en
MDR-TB
@en
MDR-TB
@fr
Multi bestanddele Tuberkulose
@af
Multidrug-Resistant TB
@en
Vank's Disease
@en
Weerstandige tuberkulose
@af
tuberculose multirésistante
@fr
tuberculosis multirresistente
@es
結核菌
@ja
prefLabel
Middelweerstandige tuberkulose
@af
multidrug-resistant tuberculosis
@en
multiresistent tuberkulos
@sv
tuberculose multirresistente
@pt
tuberculose pharmaco-résistante
@fr
tuberculosis fármaco-resistente
@es
tuberkulozo rezistema kontraŭ pluraj medikamentoj
@eo
Çok ilaca dirençli tüberküloz
@tr
שחפת עמידה
@he
مقاومة الأدوية المضادة للسل
@ar
P244
P2581
P486
P6366
P646
P1417
science/multidrug-resistant-tuberculosis
P1748
P1995
P2176
P244
sh2007003767
P2581
P2892
P3417
P486
P5270
MONDO:0005861
P6366
2777025531
P646
/m/02r7m14
P672
C01.252.410.040.552.846.775